$106.64
Today
as of Jul 22, 16:50 ET
Last 30 days
Recent Press Releases & News
BMO Capital Initiates Insmed at Outperform With $192 Price Target
Is Insmed (INSM) Priced Too Richly For Its Phase 3 Progress?
Insmed (INSM) Following TPIP 12 Month Data, Does The Valuation Still Stack Up
Overview
52-week range
$71
$213
25% of range
Avg surprise (last 3)
-6.5%
Avg reaction (last 2)
-13.6%
0% positive
Latest IV / EM
60%
EM ±13.8% · $105 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.76 | $-0.90 | +15.6% | +46.5% | -23.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-1.75 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-1.70 | $-1.30 | -30.8% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-1.42 | $-1.36 | -4.4% | — | -3.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.27 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.94 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-1.06 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-1.11 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-1.78 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$0.69 | -$1.70 | +59.4% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | $47M | — | $29M | $28M | $21M | — | $21M | $21M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-153M | — | $-366M | $-313M | $-248M | — | $-213M | $-289M |
| Net income | $-164M | — | $-370M | $-322M | $-257M | — | $-221M | $-301M |
| EPS (diluted) | $-0.76 | — | $-1.75 | $-1.70 | $-1.42 | — | $-1.27 | $-1.94 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $582M | $510M | $335M | $1.28B | $403M | $555M | $461M | $1.25B |
| Inventory | $133M | $132M | $121M | $108M | $101M | $99M | $98M | $90M |
| Total current assets | $1.61B | $1.79B | $1.93B | $2.08B | $1.40B | $1.62B | $1.65B | $1.42B |
| Total assets | $2.08B | $2.26B | $2.36B | $2.48B | $1.80B | $2.03B | $2.05B | $1.81B |
| Long-term debt | $542M | $541M | $540M | $539M | $1.11B | $1.10B | $955M | $947M |
| Total liabilities | $1.37B | $1.53B | $1.42B | $1.23B | $1.70B | $1.74B | $1.57B | $1.77B |
| Total equity | $705M | $739M | $946M | $1.25B | $99M | $285M | $483M | $39M |